finnCap have raised £11m for Omega Diagnostics Group, an AIM-listed molecular diagnostics firm.

The funds will be used to exploit opportunities the Company currently has with COVID19 testing, to scale up manufacturing, to undertake work to improve the margin of its VISITECT® CD4 products and to expand its lateral flow product portfolio with products which are complementary to its VISITECT® CD4 products.